{"id":"dtacp","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Vascular leak syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DTacP combines diphtheria toxin with targeting moieties to deliver cytotoxic payload to cancer cells. The mechanism leverages the potent protein synthesis inhibition activity of diphtheria toxin while directing it selectively to tumor cells, thereby reducing systemic toxicity compared to untargeted chemotherapy.","oneSentence":"DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:06.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT07112144","phase":"PHASE3","title":"Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial","status":"RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-06-13","conditions":"Prevent Whooping Cough, Prevent Diphtheria, Prevent Tetanus","enrollment":1650},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT00654901","phase":"PHASE3","title":"Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":881},{"nctId":"NCT01491087","phase":"PHASE4","title":"Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":900},{"nctId":"NCT00303316","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":458},{"nctId":"NCT00453570","phase":"PHASE3","title":"Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Diphtheria, Tetanus, Haemophilus Influenzae Type b","enrollment":792},{"nctId":"NCT01214889","phase":"PHASE3","title":"Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":370},{"nctId":"NCT00259337","phase":"PHASE3","title":"Immunogenicity and Safety of Pentaxim™ in an Indian Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diphtheria, Tetanus, Polio","enrollment":226},{"nctId":"NCT01031303","phase":"PHASE4","title":"Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-12","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":123}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DTacP","genericName":"DTacP","companyName":"Changchun BCHT Biotechnology Co.","companyId":"changchun-bcht-biotechnology-co","modality":"Biologic","firstApprovalDate":"","aiSummary":"DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens. Used for Solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}